-+ 0.00%
-+ 0.00%
-+ 0.00%

SELLAS Life Sciences Announces Topline Results From Its Phase 3 REGAL Trial Evaluating Galinpepimut-S In Patients With Acute Myeloid Leukemia Met Primary Endpoint

Benzinga·11/17/2026 12:06:03

REGAL trial met its primary endpoint with GPS demonstrating statistically significant and clinically meaningful reduction in risk of death by 41% with median overall survival of 24.0 months versus 14.7 months for best available treatment, and a hazard ratio of 0.59 (p=0.035) -

- Company plans to meet with the U.S. Food and Drug Administration (FDA) while advancing preparations for a Biologics License Application (BLA) submission for GPS -

- SELLAS to host webcast today, November 17, 2026, at 7:45 a.m. Eastern Time -